Drug Patents Expiring in 2037
1. Adlarity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11679086 | CORIUM | Systems comprising a composite backing and methods for long term transdermal administration |
May, 2037
(12 years from now) | |
| US11103463 | CORIUM | Methods for treating alzheimer's disease with donepezil transdermal system |
Jul, 2037
(12 years from now) | |
| US10300025 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(12 years from now) | |
| US10016372 | CORIUM | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
Jul, 2037
(12 years from now) | |
| US10307379 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(12 years from now) | |
| US9993466 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(12 years from now) | |
| US11648214 | CORIUM | Systems and methods for long term transdermal administration |
Sep, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 11, 2025 |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient
Market Authorisation Date: 11 March, 2022
Treatment: A method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type
Dosage: SYSTEM
More Information on Dosage
ADLARITY family patents
2. Airduo Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10569034 (Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
AIRDUO DIGIHALER family patents
3. Akeega patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11986468 | JANSSEN BIOTECH | Methods of treating prostate cancer |
Jul, 2037
(12 years from now) | |
| US11986469 | JANSSEN BIOTECH | Methods of treating prostate cancer |
Jul, 2037
(12 years from now) | |
| US11207311 | JANSSEN BIOTECH | Method of treating prostate cancer |
Jul, 2037
(12 years from now) | |
| US11992486 | JANSSEN BIOTECH | Methods of treating prostate cancer |
Jul, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 11, 2026 |
Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 11 August, 2023
Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation
Dosage: TABLET
More Information on Dosage
AKEEGA family patents
4. Akynzeo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10624911 | HELSINN HLTHCARE | Physiologically balanced injectable formulations of fosnetupitant |
Jun, 2037
(12 years from now) | |
| US11529362 | HELSINN HLTHCARE | Physiologically balanced injectable formulations of fosnetupitant |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 19, 2023 |
NCE-1 date: 19 April, 2022
Market Authorisation Date: 19 April, 2018
Treatment: NA
Dosage: SOLUTION; POWDER
More Information on Dosage
AKYNZEO family patents
5. Amzeeq patent expiration
Can you believe AMZEEQ received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10398641 | JOURNEY | Compositions and methods for treating rosacea and acne |
Sep, 2037
(12 years from now) | |
| US10849847 | JOURNEY | Compositions and methods for treating rosacea and acne |
Sep, 2037
(12 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 October, 2019
Treatment: Treatment of non-nodular acne vulgaris
Dosage: AEROSOL, FOAM
More Information on Dosage
AMZEEQ family patents
6. Armonair Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10569034 (Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARMONAIR DIGIHALER family patents
7. Atorvaliq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11369567 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(12 years from now) | |
| US11654106 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(12 years from now) | |
| US11925704 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(12 years from now) | |
Drugs and Companies using ATORVASTATIN CALCIUM ingredient
Market Authorisation Date: 01 February, 2023
Treatment: As an adjunct to other low-density lipoprotein cholesterol (ldl-c) lowering therapies, or alone if such treatments are unavailable, to reduce ldl-c in adults and pediatric patients aged 10 years and o...
Dosage: SUSPENSION
More Information on Dosage
ATORVALIQ family patents
8. Auvi-q patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10842938 | KALEO INC | Medicament delivery device and methods for delivering drugs to infants and children |
Dec, 2037
(13 years from now) | |
| US10688244 | KALEO INC | Medicament delivery device and methods for delivering drugs to infants and children |
Dec, 2037
(13 years from now) | |
| US11771830 | KALEO INC | Medicament delivery device and methods for delivering drugs to infants and children |
Dec, 2037
(13 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 17 November, 2017
Treatment: Method of treating an allergic reaction using an auto-injector
Dosage: SOLUTION
More Information on Dosage
AUVI-Q family patents
9. Azstarys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10584112 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10584113 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(12 years from now) | |
| US10759778 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(12 years from now) | |
| US10858341 | COMMAVE THERAP | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(12 years from now) | |
| US10954213 | COMMAVE THERAP | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 07, 2026 |
NCE-1 date: 07 May, 2025
Market Authorisation Date: 07 May, 2021
Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate
Dosage: CAPSULE
More Information on Dosage
AZSTARYS family patents
10. Bludigo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11499050 | PROVEPHARM SAS | Process for the preparation of indigotindisulfonate sodium (indigo carmine) |
Dec, 2037
(13 years from now) | |
| US10927258 | PROVEPHARM SAS | Process for the preparation of Indigotindisulfonate sodium (indigo carmine) |
Dec, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 08, 2027 |
Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient
NCE-1 date: 08 July, 2026
Market Authorisation Date: 08 July, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
BLUDIGO family patents
11. Brukinsa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11851437 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| US10927117 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11970500 | BEIGENE | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| US11591340 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| US11884674 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-871) | Aug 31, 2024 |
| New Indication(I-874) | Sep 14, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| New Indication(I-817) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
| New Indication(I-936) | Mar 07, 2027 |
| Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
| Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
| Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
| Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia (cll) who have received at least one p...
Dosage: CAPSULE
More Information on Dosage
BRUKINSA family patents
12. Cabometyx patent expiration
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11141413 | EXELIXIS INC | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
Apr, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
| New Product(NP) | Apr 25, 2019 |
| New Indication(I-760) | Dec 19, 2020 |
| New Indication(I-792) | Jan 14, 2022 |
| New Indication(I-854) | Jan 22, 2024 |
| New Indication(I-873) | Sep 17, 2024 |
| Orphan Drug Exclusivity(ODE-227) | Jan 14, 2026 |
| Orphan Drug Exclusivity(ODE-375) | Sep 17, 2028 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 25 April, 2016
Treatment: Treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy
Dosage: TABLET
More Information on Dosage
CABOMETYX family patents
13. Calcium Gluconate In Sodium Chloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10342813 | HQ SPCLT PHARMA | Calcium gluconate solutions in flexible containers |
Jul, 2037
(12 years from now) | |
| US10130646 | HQ SPCLT PHARMA | Calcium gluconate solutions in flexible containers |
Jul, 2037
(12 years from now) | |
Drugs and Companies using CALCIUM GLUCONATE ingredient
Market Authorisation Date: 29 October, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
CALCIUM GLUCONATE IN SODIUM CHLORIDE family patents
14. Cequa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10918694 | SUN PHARM | Topical cyclosporine-containing formulations and uses thereof |
Feb, 2037
(12 years from now) | |
| US11951153 | SUN PHARM | Topical cyclosporine-containing formulations and uses thereof |
Feb, 2037
(12 years from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 14 August, 2018
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: SOLUTION
More Information on Dosage
CEQUA family patents
15. Definity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857646 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US11266750 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US11529431 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US10583208 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US11925695 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US9789210 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US10588988 | LANTHEUS MEDCL | Methods and devices for preparation of ultrasound contrast agents |
May, 2037
(12 years from now) | |
Drugs and Companies using PERFLUTREN ingredient
Market Authorisation Date: 31 July, 2001
Treatment: Method of using the drug substance/drug product for ultrasound imaging
Dosage: INJECTABLE
More Information on Dosage
DEFINITY family patents
16. Definity Rt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857646 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US10583208 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US9789210 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US11529431 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US11266750 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US11925695 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US10588988 | LANTHEUS MEDCL | Methods and devices for preparation of ultrasound contrast agents |
May, 2037
(12 years from now) | |
Drugs and Companies using PERFLUTREN ingredient
Market Authorisation Date: 31 July, 2001
Treatment: Method of using the drug substance/drug product for ultrasound imaging
Dosage: INJECTABLE
More Information on Dosage
DEFINITY RT family patents
17. Dextenza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458041 | OCULAR THERAPEUTIX | Punctal plug and bioadhesives |
Nov, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 30, 2021 |
| New Indication(I-800) | Jun 20, 2022 |
| New Indication(I-876) | Oct 07, 2024 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: Treatment of ocular inflammation and pain following ophthalmic surgery
Dosage: INSERT
More Information on Dosage
DEXTENZA family patents
18. Drizalma Sprinkle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11202772 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(12 years from now) | |
| US10413525 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(12 years from now) | |
| US9839626 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(12 years from now) | |
| US10959982 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(12 years from now) | |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 July, 2019
Treatment: NA
Dosage: CAPSULE, DELAYED REL PELLETS
More Information on Dosage
DRIZALMA SPRINKLE family patents
19. Edurant Ped patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11065198 | JANSSEN PRODS | Dispersible compositions |
Oct, 2037
(12 years from now) | |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 March, 2024
Treatment: NA
Dosage: TABLET, FOR SUSPENSION
More Information on Dosage
EDURANT PED family patents
20. Entresto Sprinkle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10722471 | NOVARTIS | Galenic formulations of organic compounds |
Feb, 2037
(12 years from now) | |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
Market Authorisation Date: 12 April, 2024
Treatment: Treatment of heart failure with oral pellets
Dosage: CAPSULE, PELLETS
More Information on Dosage
ENTRESTO SPRINKLE family patents
21. Esbriet patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188637 | GENENTECH INC | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Mar, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 11 January, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
ESBRIET family patents
22. Evekeo Odt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11896562 | AZURITY | Oral amphetamine composition |
Mar, 2037
(12 years from now) | |
| US11160772 | AZURITY | Oral amphetamine composition |
Mar, 2037
(12 years from now) | |
| US10441554 | AZURITY | Oral amphetamine composition |
Mar, 2037
(12 years from now) | |
Drugs and Companies using AMPHETAMINE SULFATE ingredient
Market Authorisation Date: 16 April, 2021
Treatment: Treatment of attention deficit hyperactivity disorder (adhd) in pediatric patients
Dosage: TABLET, ORALLY DISINTEGRATING
More Information on Dosage
EVEKEO ODT family patents
23. Fintepla patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10947183 (Pediatric) | UCB INC | Fenfluramine compositions and methods of preparing the same |
Jun, 2037
(12 years from now) | |
| US11759440 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(12 years from now) | |
| US10603290 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(12 years from now) | |
| US11040018 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(12 years from now) | |
| US11406606 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(12 years from now) | |
| US11786487 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 25, 2023 |
| New Indication(I-887) | Mar 25, 2025 |
| Orphan Drug Exclusivity(ODE-312) | Jun 25, 2027 |
| Orphan Drug Exclusivity(ODE-393) | Mar 25, 2029 |
| Pediatric Exclusivity(PED) | Sep 25, 2029 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Treatment: Method of reducing or ameliorating seizures in a patient by administering a liquid formulation of fenfluramine with stiripentol thereby modulating down the formation of norfenfluramine and resulting i...
Dosage: SOLUTION
More Information on Dosage
FINTEPLA family patents
24. Firdapse patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10626088 | CATALYST PHARMS | Determining degradation of 3,4-diaminopyridine |
Feb, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 28, 2023 |
| New Patient Population(NPP) | Sep 29, 2025 |
| Orphan Drug Exclusivity(ODE-223) | Nov 28, 2025 |
Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient
NCE-1 date: 28 November, 2022
Market Authorisation Date: 28 November, 2018
Treatment: NA
Dosage: TABLET
More Information on Dosage
FIRDAPSE family patents
25. Fleqsuvy patent expiration
Can you believe FLEQSUVY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446246 | AZURITY | Suspensions and diluents for metronidazole and baclofen |
Sep, 2037
(12 years from now) | |
| US11324696 | AZURITY | Suspensions and diluents for metronidazole and baclofen |
Sep, 2037
(12 years from now) | |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 04 February, 2022
Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis
Dosage: SUSPENSION
More Information on Dosage
FLEQSUVY family patents
26. Fluorescein Sodium And Benoxinate Hydrochloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10632197 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(12 years from now) | |
| US10293047 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(12 years from now) | |
| US10842872 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(12 years from now) | |
Drugs and Companies using BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM ingredient
Market Authorisation Date: 09 March, 2020
Treatment: Ocular examination, intraocular pressure measurement, or removal of foreign bodies or sutures, in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic ane...
Dosage: SOLUTION/DROPS
More Information on Dosage
FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE family patents
27. Galafold patent expiration
Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11234972 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(12 years from now) | |
| US10076514 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity(ODE-205) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients
Dosage: CAPSULE
More Information on Dosage
GALAFOLD family patents
28. Giapreza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11219662 | LA JOLLA PHARMA | Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II |
Jan, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2022 |
Drugs and Companies using ANGIOTENSIN II ACETATE ingredient
NCE-1 date: 21 December, 2021
Market Authorisation Date: 23 December, 2021
Treatment: Treating hypotension with angiotensin ii in a patient receiving an angiotensin converting enzyme inhibitor
Dosage: SOLUTION
How can I launch a generic of GIAPREZA before it's drug patent expiration?
More Information on Dosage
GIAPREZA family patents
29. Gloperba patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10226423 | SCILEX PHARMS | Colchicine drug-to-drug interactions |
Dec, 2037
(13 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 30 January, 2019
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
GLOPERBA family patents
30. Goprelto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10987347 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10413505 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US9867815 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10894012 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10149843 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US11040032 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10016407 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10420760 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10857095 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10231961 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10933060 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10973811 | NODEN PHARMA | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2022 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2021
Market Authorisation Date: 14 December, 2017
Treatment: Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; Method of administering a local anesthetic to the mucous membranes; Method of administering a lo...
Dosage: SOLUTION
More Information on Dosage
GOPRELTO family patents
31. Hemady patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11304961 | DEXCEL | Compositions comprising dexamethasone |
Dec, 2037
(13 years from now) | |
| US10537585 | DEXCEL | Compositions comprising dexamethasone |
Dec, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-271) | Oct 03, 2026 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 03 October, 2019
Treatment: A method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product
Dosage: TABLET
More Information on Dosage
HEMADY family patents
32. Igalmi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11839604 | BIOXCEL | Use of sublingual dexmedetomidine for the treatment of agitation |
Dec, 2037
(13 years from now) | |
| US11786508 | BIOXCEL | Use of sublingual dexmedetomidine for the treatment of agitation |
Dec, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with bipolar i or ii disorder by sublingual or buccal administration; Acute treatment of agitation associated with schizophrenia by sublingual or buccal adminis...
Dosage: FILM
More Information on Dosage
IGALMI family patents
33. Ingrezza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10912771 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| US10857148 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| US10993941 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| US10952997 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| US10874648 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| US10857137 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| US11439629 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| US11040029 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2022 |
| New Indication(I-925) | Aug 18, 2026 |
| Orphan Drug Exclusivity(ODE-440) | Aug 18, 2030 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: 11 April, 2021
Market Authorisation Date: 11 April, 2017
Treatment: Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer; Treatment of tardive dyskinesia; A method of treating huntington's chorea
Dosage: CAPSULE
How can I launch a generic of INGREZZA before it's drug patent expiration?
More Information on Dosage
INGREZZA family patents
34. Ingrezza Sprinkle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10993941 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| US10912771 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| US10952997 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| US11040029 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| US11439629 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| US10857137 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| US10874648 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| US10857148 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-925) | Aug 18, 2026 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
Market Authorisation Date: 30 April, 2024
Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea
Dosage: CAPSULE
More Information on Dosage
INGREZZA SPRINKLE family patents
35. Inlyta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10869924 | PF PRISM CV | PD-L1 antagonist combination treatments |
Jan, 2037
(12 years from now) | |
|
US10869924 (Pediatric) | PF PRISM CV | PD-L1 antagonist combination treatments |
Jul, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2017 |
Drugs and Companies using AXITINIB ingredient
NCE-1 date: 28 January, 2016
Market Authorisation Date: 27 January, 2012
Treatment: Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma
Dosage: TABLET
More Information on Dosage
INLYTA family patents
36. Iqirvo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11850223 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
| US11331292 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
| US11857523 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
| US11185519 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Jun 10, 2031 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Treatment: Treatment of primary biliary cholangitis (pbc); Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults who have had an inadequate response to udca, or...
Dosage: TABLET
More Information on Dosage
IQIRVO family patents
37. Katerzia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10894039 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
| US12053461 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
| US11364230 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
| US11701326 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
| US11918685 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
| US10959991 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
| US11471409 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
| US10952998 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
| US11484498 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
| US10695329 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
Drugs and Companies using AMLODIPINE BENZOATE ingredient
Market Authorisation Date: 08 July, 2019
Treatment: Method of treating hypertension; A method of treating hypertension; Angina
Dosage: SUSPENSION
More Information on Dosage
KATERZIA family patents
38. Korlym patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10151763 | CORCEPT THERAP | Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome |
Jan, 2037
(12 years from now) | |
| US10195214 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(12 years from now) | |
| US10842800 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(12 years from now) | |
| US12097210 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(12 years from now) | |
| US11969435 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 17, 2015 |
| Orphan Drug Exclusivity(ODE) | Feb 17, 2019 |
| Orphan Drug Exclusivity(ODE-22) | Feb 17, 2019 |
Drugs and Companies using MIFEPRISTONE ingredient
Market Authorisation Date: 17 February, 2012
Treatment: Treating cushing's syndrome
Dosage: TABLET
More Information on Dosage
KORLYM family patents
39. Krazati patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10689377 | BRISTOL | KRas G12C inhibitors |
May, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2027 |
| Orphan Drug Exclusivity(ODE-352) | Dec 12, 2029 |
Drugs and Companies using ADAGRASIB ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 12 December, 2022
Treatment: Treatment, in combination with cetuximab, of adult patients with kras g12c-muted locally advanced or metastatic colorectal cancer, per fda approved test, where prior treatment with fluoropyrimidine-, ...
Dosage: TABLET
More Information on Dosage
KRAZATI family patents
40. Leqselvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12076323 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
May, 2037
(12 years from now) | |
| US10561659 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
May, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 25, 2029 |
Drugs and Companies using DEURUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 25 July, 2028
Market Authorisation Date: 25 July, 2024
Treatment: Treatment of adult patients with alopecia areata
Dosage: TABLET
More Information on Dosage
LEQSELVI family patents
41. Lexette patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10857159 (Pediatric) | MAYNE PHARMA | Halobetasol foam composition and method of use thereof |
May, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 24, 2021 |
| New Patient Population(NPP) | Aug 18, 2024 |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 24 May, 2018
Treatment: NA
Dosage: AEROSOL, FOAM
More Information on Dosage
LEXETTE family patents
42. Lonsurf patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10456399 | TAIHO ONCOLOGY | Method for treating cancer patients with severe renal impairment |
Feb, 2037
(12 years from now) | |
| US10960004 | TAIHO ONCOLOGY | Method for treating cancer patients with severe renal impairment |
Feb, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2020 |
| New Indication(I-794) | Feb 22, 2022 |
| Orphan Drug Exclusivity(ODE-229) | Feb 22, 2026 |
Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient
NCE-1 date: 23 September, 2019
Market Authorisation Date: 22 September, 2015
Treatment: Treatment of metastatic colorectal cancer alone or with bevacizumab in severely renally impaired patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan therapy, an anti-vegf b...
Dosage: TABLET
More Information on Dosage
LONSURF family patents
43. Lumryz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10973795 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11602513 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11602512 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11400065 | AVADEL CNS | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
Jul, 2037
(12 years from now) | |
| US11986451 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US10952986 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11826335 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US12097176 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11896572 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11839597 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US12109186 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11766418 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11065224 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US10272062 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US12115143 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US12115144 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US12115142 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11504347 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US12097175 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US12115145 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11052061 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US10736866 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| US11000498 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 01, 2026 |
| Orphan Drug Exclusivity(ODE-431) | May 01, 2030 |
| Orphan Drug Exclusivity(ODE-494) | Oct 16, 2031 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 01 May, 2023
Treatment: Treatment of narcolepsy-related cataplexy or excessive daytime sleepiness using a once-daily pharmaceutical formulation comprising an oxybate; Treatment of narcolepsy-related cataplexy or excessive da...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
LUMRYZ family patents
44. Lupkynis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11622991 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(12 years from now) | |
| US10286036 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 22 January, 2025
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE
More Information on Dosage
LUPKYNIS family patents
45. Miebo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10507132 | BAUSCH AND LOMB INC | Topical administration method |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 18, 2028 |
Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient
NCE-1 date: 19 May, 2027
Market Authorisation Date: 18 May, 2023
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS
More Information on Dosage
MIEBO family patents
46. Myfembree patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033551 | SUMITOMO PHARMA | Methods of treating uterine fibroids |
Sep, 2037
(12 years from now) | |
| US11957684 | SUMITOMO PHARMA | Treatment of heavy menstrual bleeding associated with uterine fibroids |
Sep, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 26, 2024 |
| New Indication(I-898) | Aug 05, 2025 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
| M(M-289) | Jan 27, 2026 |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 26 May, 2021
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women
Dosage: TABLET
More Information on Dosage
MYFEMBREE family patents
47. Numbrino patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10933060 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US9867815 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10973811 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10894012 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10420760 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10857095 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10413505 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10149843 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10016407 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10231961 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US11040032 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2022 |
| New Product(NP) | Jan 10, 2023 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2021
Market Authorisation Date: 10 January, 2020
Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic to the mucous membranes in patients with renal impairment; A method for treating a subj...
Dosage: SOLUTION
More Information on Dosage
NUMBRINO family patents
48. Nuplazid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10517860 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(12 years from now) | |
| US10953000 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2021 |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
NCE-1 date: 29 April, 2020
Market Authorisation Date: 28 June, 2018
Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis
Dosage: TABLET
More Information on Dosage
NUPLAZID family patents
49. Nuzyra patent expiration
Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10111890 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and uses thereof |
Aug, 2037
(12 years from now) | |
| US10835542 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(12 years from now) | |
| US10383884 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 02, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 02, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 03 October, 2027
Market Authorisation Date: 02 October, 2018
Treatment: Treatment of subjects having bacterial skin or skin structure infection; Treatment of community acquired bacterial pneumonia
Dosage: TABLET; POWDER
More Information on Dosage
NUZYRA family patents
50. Opfolda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857212 | AMICUS THERAP US | Augmented acid alpha-glucosidase for the treatment of Pompe disease |
Aug, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2026 |
Drugs and Companies using MIGLUSTAT ingredient
Market Authorisation Date: 28 September, 2023
Treatment: The treatment of pompe patients
Dosage: CAPSULE
More Information on Dosage
OPFOLDA family patents
51. Orgovyx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10786501 | SUMITOMO PHARMA | Treatment of prostate cancer |
Sep, 2037
(12 years from now) | |
| US10449191 | SUMITOMO PHARMA | Treatment of prostate cancer |
Sep, 2037
(12 years from now) | |
| US12097198 | SUMITOMO PHARMA | Treatment of prostate cancer |
Sep, 2037
(12 years from now) | |
| US11583526 | SUMITOMO PHARMA | Treatment of prostate cancer |
Sep, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 18 December, 2020
Treatment: Treatment of adult patients with advanced prostate cancer
Dosage: TABLET
More Information on Dosage
ORGOVYX family patents
52. Otiprio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11040004 | ALK ABELLO | Otic gel formulations for treating otitis externa |
Nov, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 10, 2018 |
| New Indication(I-770) | Mar 02, 2021 |
Drugs and Companies using CIPROFLOXACIN ingredient
Market Authorisation Date: 10 December, 2015
Treatment: The treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas aeruginosa and staphylococcus aureus
Dosage: INJECTABLE, SUSPENSION
More Information on Dosage
OTIPRIO family patents
53. Oxbryta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10493035 | GLOBAL BLOOD THERAPS | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Oct, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 25, 2024 |
| Orphan Drug Exclusivity(ODE-281) | Nov 25, 2026 |
| Orphan Drug Exclusivity(ODE-394) | Dec 17, 2028 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: 26 November, 2023
Market Authorisation Date: 14 October, 2022
Treatment: NA
Dosage: TABLET
More Information on Dosage
OXBRYTA family patents
54. Pizensy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10806743 | BRAINTREE LABS | Method of administering lactitol to reduce plasma concentration of lactitol |
May, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2025 |
Drugs and Companies using LACTITOL ingredient
NCE-1 date: 13 February, 2024
Market Authorisation Date: 12 February, 2020
Treatment: Method of treating chronic idiopathic constipation in adult patients.
Dosage: FOR SOLUTION
More Information on Dosage
PIZENSY family patents
55. Procysbi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10905662 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(12 years from now) | |
|
US10328037 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(12 years from now) | |
|
US10143665 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(12 years from now) | |
|
US10548859 (Pediatric) | HORIZON | Methods for storing Cysteamine formulations and related methods of treatment |
Feb, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Apr 30, 2016 |
| New Patient Population(NPP) | Aug 14, 2018 |
| Orphan Drug Exclusivity(ODE-45) | Apr 30, 2020 |
| M(M-216) | Dec 22, 2020 |
| Orphan Drug Exclusivity(ODE) | Aug 14, 2022 |
| Orphan Drug Exclusivity(ODE-97) | Aug 14, 2022 |
| ODE*(ODE*) | Dec 22, 2024 |
| Orphan Drug Exclusivity(ODE-162) | Dec 22, 2024 |
| Pediatric Exclusivity(PED) | Jun 22, 2025 |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Market Authorisation Date: 30 April, 2013
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE; GRANULE, DELAYED RELEASE
How can I launch a generic of PROCYSBI before it's drug patent expiration?
More Information on Dosage
PROCYSBI family patents
56. Pylarify patent expiration
Can you believe PYLARIFY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11851407 | PROGENICS PHARMS INC | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL |
Jun, 2037
(12 years from now) | |
| US10947197 | PROGENICS PHARMS INC | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2026 |
Drugs and Companies using PIFLUFOLASTAT F-18 ingredient
NCE-1 date: 26 May, 2025
Market Authorisation Date: 26 May, 2021
Treatment: Method of positron emission tomography (pet) in men with prostate cancer
Dosage: SOLUTION
More Information on Dosage
PYLARIFY family patents
57. Qlosi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10639297 | ORASIS PHARMS | Ophthalmic pharmaceutical compositions and uses relating thereto |
Aug, 2037
(12 years from now) | |
| US11974986 | ORASIS PHARMS | Ophthalmic pharmaceutical compositions and uses relating thereto |
Aug, 2037
(12 years from now) | |
| US11129812 | ORASIS PHARMS | Ophthalmic pharmaceutical compositions and uses relating thereto |
Aug, 2037
(12 years from now) | |
| US9867810 | ORASIS PHARMS | Ophthalmic pharmaceutical compositions and uses relating thereto |
Aug, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 17, 2026 |
Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 October, 2023
Treatment: Treatment of presbyopia
Dosage: SOLUTION
More Information on Dosage
QLOSI family patents
58. Retevmo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10112942 | LOXO ONCOL ELI LILLY | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10137124 | LOXO ONCOL ELI LILLY | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(12 years from now) | |
| US10172851 | LOXO ONCOL ELI LILLY | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 08, 2025 |
| Orphan Drug Exclusivity(ODE-301) | May 08, 2027 |
| Orphan Drug Exclusivity(ODE-302) | May 08, 2027 |
| Orphan Drug Exclusivity(ODE-303) | May 08, 2027 |
| New Patient Population(NPP) | May 29, 2027 |
| Orphan Drug Exclusivity(ODE-409) | Sep 21, 2029 |
| Orphan Drug Exclusivity(ODE-412) | Sep 21, 2029 |
| Orphan Drug Exclusivity(ODE-484) | May 29, 2031 |
| Orphan Drug Exclusivity(ODE-485) | May 29, 2031 |
| Orphan Drug Exclusivity(ODE-487) | May 29, 2031 |
Drugs and Companies using SELPERCATINIB ingredient
NCE-1 date: 08 May, 2024
Market Authorisation Date: 08 May, 2020
Treatment: Treatment of adult or pediatric patients 2 years of age or older with advanced or metastatic thyroid cancer with a ret gene fusion, as detected by an fda-approved test, who require systemic therapy an...
Dosage: CAPSULE; TABLET
More Information on Dosage
RETEVMO family patents
59. Reyvow patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11053214 | ELI LILLY AND CO | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
Dec, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2025 |
Drugs and Companies using LASMIDITAN SUCCINATE ingredient
NCE-1 date: 01 February, 2024
Market Authorisation Date: 31 January, 2020
Treatment: Acute treatment of migraine
Dosage: TABLET
More Information on Dosage
REYVOW family patents
60. Rezzayo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11712459 | MUNDIPHARMA | Dosing regimens for treatment of fungal infections |
Mar, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2028 |
| Orphan Drug Exclusivity(ODE-426) | Mar 22, 2030 |
| Generating Antibiotic Incentives Now(GAIN) | Mar 22, 2033 |
Drugs and Companies using REZAFUNGIN ACETATE ingredient
NCE-1 date: 22 March, 2032
Market Authorisation Date: 22 March, 2023
Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration
Dosage: POWDER
More Information on Dosage
REZZAYO family patents
61. Rozlytrek patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10738037 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11091469 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 15, 2024 |
| Orphan Drug Exclusivity(ODE-265) | Aug 15, 2026 |
| Orphan Drug Exclusivity(ODE-313) | Aug 15, 2026 |
| New Product(NP) | Oct 20, 2026 |
| New Patient Population(NPP) | Oct 20, 2026 |
| Orphan Drug Exclusivity(ODE-448) | Oct 20, 2030 |
Drugs and Companies using ENTRECTINIB ingredient
NCE-1 date: 16 August, 2023
Market Authorisation Date: 15 August, 2019
Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of colorectal cancer that has a neurotrophic tyrosine receptor kinase(ntrk) gene fusion
Dosage: CAPSULE
More Information on Dosage
ROZLYTREK family patents
62. Saxenda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9968659 | NOVO | Liraglutide in cardiovascular conditions |
Jan, 2037
(12 years from now) | |
|
US9968659 (Pediatric) | NOVO | Liraglutide in cardiovascular conditions |
Jul, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| New Product(NP) | Jan 25, 2017 |
| New Patient Population(NPP) | Dec 04, 2023 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease
Dosage: SOLUTION
How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage
SAXENDA family patents
63. Sofdra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11123325 | BOTANIX SB | Formulation for soft anticholinergic analogs |
Jul, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2029 |
Drugs and Companies using SOFPIRONIUM BROMIDE ingredient
NCE-1 date: 20 June, 2028
Market Authorisation Date: 18 June, 2024
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: GEL, METERED
More Information on Dosage
SOFDRA family patents
64. Sohonos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10864194 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(12 years from now) | |
| US11622959 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2028 |
| Orphan Drug Exclusivity(ODE-439) | Aug 16, 2030 |
Drugs and Companies using PALOVAROTENE ingredient
NCE-1 date: 17 August, 2027
Market Authorisation Date: 16 August, 2023
Treatment: Reduction of heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva
Dosage: CAPSULE
More Information on Dosage
SOHONOS family patents
65. Sunlenca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10071985 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10654827 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2027 |
Drugs and Companies using LENACAPAVIR SODIUM ingredient
NCE-1 date: 22 December, 2026
Market Authorisation Date: 22 December, 2022
Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection
Dosage: TABLET; SOLUTION
More Information on Dosage
SUNLENCA family patents
66. Sunosi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11998639 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
| US10195151 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
| US11439597 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
| US10512609 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa)
Dosage: TABLET
More Information on Dosage
SUNOSI family patents
67. Sutab patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10143656 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
Aug, 2037
(12 years from now) | |
| US11638697 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
Aug, 2037
(12 years from now) | |
| US11382864 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleansing a colon and methods of using same |
Aug, 2037
(12 years from now) | |
| US11033498 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
Aug, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 10, 2023 |
Drugs and Companies using MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE ingredient
Market Authorisation Date: 10 November, 2020
Treatment: Gastrointestinal tablets indicated for cleansing the colon in preparation for colonoscopy
Dosage: TABLET
More Information on Dosage
SUTAB family patents
68. Syfovre patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11903994 | APELLIS PHARMS | Dosing regimens |
Feb, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 22, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of 15 mg pegcetacoplan monthly or every other month
Dosage: SOLUTION
More Information on Dosage
SYFOVRE family patents
69. Terlivaz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335452 | MALLINCKRODT IRELAND | Method of treating patients with hepatorenal syndrome type 1 |
Apr, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 14, 2027 |
| Orphan Drug Exclusivity(ODE-406) | Sep 14, 2029 |
Drugs and Companies using TERLIPRESSIN ACETATE ingredient
NCE-1 date: 14 September, 2026
Market Authorisation Date: 14 September, 2022
Treatment: A method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function
Dosage: POWDER
More Information on Dosage
TERLIVAZ family patents
70. Tirosint-sol patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11096913 | IBSA | High-stability packaged solutions of T4 thyroid hormone |
Feb, 2037
(12 years from now) | |
| US10537538 | IBSA | High-stability packaged solutions of T4 thyroid hormone |
Feb, 2037
(12 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 15 December, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TIROSINT-SOL family patents
71. Tlando patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11559530 | VERITY | Oral testosterone undecanoate therapy |
Nov, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 28, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 28 March, 2022
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: CAPSULE
More Information on Dosage
TLANDO family patents
72. Trikafta (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11453655 | VERTEX PHARMS INC | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Dec, 2037
(12 years from now) | |
| US10793547 | VERTEX PHARMS INC | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Dec, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11517564 | VERTEX PHARMS INC | Methods of treatment for cystic fibrosis |
Dec, 2037
(12 years from now) | |
| US11179367 | VERTEX PHARMS INC | Pharmaceutical compositions for treating cystic fibrosis |
Dec, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 08, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2024 |
| New Product(NP) | Apr 26, 2026 |
| Orphan Drug Exclusivity(ODE-275) | Oct 21, 2026 |
| Orphan Drug Exclusivity(ODE-323) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-357) | Jun 08, 2028 |
| Orphan Drug Exclusivity(ODE-433) | Apr 26, 2030 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 22 October, 2023
Market Authorisation Date: 26 April, 2023
Treatment: Treatment of cystic fibrosis in patients aged 2 to <6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data by administering d...
Dosage: GRANULES; TABLET
More Information on Dosage
TRIKAFTA (COPACKAGED) family patents
73. Tryvio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11174247 | IDORSIA | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Nov, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2029 |
Drugs and Companies using APROCITENTAN ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 19 March, 2024
Treatment: Treatment of hypertension in combination with other antihypertensive drugs, including an angiotensin receptor blocker, to lower blood pressure in adult patients who are not adequately controlled on ot...
Dosage: TABLET
More Information on Dosage
TRYVIO family patents
74. Veklury patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10695361 (Pediatric) | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Mar, 2037
(12 years from now) | |
|
US11382926 (Pediatric) | GILEAD SCIENCES INC | Methods for treating Arenaviridae and Coronaviridae virus infections |
Mar, 2037
(12 years from now) | |
|
US11007208 (Pediatric) | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Mar, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-183) | Jan 21, 2025 |
| New Patient Population(NPP) | Apr 25, 2025 |
| New Chemical Entity Exclusivity(NCE) | Oct 22, 2025 |
| M(M-301) | Jul 13, 2026 |
| Pediatric Exclusivity(PED) | Jan 13, 2027 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: 13 January, 2026
Market Authorisation Date: 22 October, 2020
Treatment: NA
Dosage: POWDER; SOLUTION
More Information on Dosage
VEKLURY family patents
75. Vevye patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10813976 | HARROW EYE | Ophthalmic compositions comprising ciclosporin |
Sep, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 30, 2026 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 30 May, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
VEVYE family patents
76. Victoza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9968659 | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jan, 2037
(12 years from now) | |
|
US9968659 (Pediatric) | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jul, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| M(M-115) | Apr 06, 2015 |
| M(M-176) | Apr 22, 2019 |
| New Indication(I-750) | Aug 25, 2020 |
| New Patient Population(NPP) | Jun 17, 2022 |
| Pediatric Exclusivity(PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administ...
Dosage: SOLUTION
How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage
VICTOZA family patents
77. Vitrakvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10137127 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(12 years from now) | |
| US10045991 | BAYER HEALTHCARE | Methods of treating pediatric cancers |
Apr, 2037
(12 years from now) | |
| US10668072 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(12 years from now) | |
| US11484535 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(12 years from now) | |
| US11191766 | BAYER HEALTHCARE | Methods of treating pediatric cancers |
Apr, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 26, 2023 |
| Orphan Drug Exclusivity(ODE-215) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-220) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-221) | Nov 26, 2025 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: 26 November, 2022
Market Authorisation Date: 26 November, 2018
Treatment: Method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusion in a pediatric patient with an oral solution; Method of treating...
Dosage: SOLUTION
More Information on Dosage
VITRAKVI family patents
78. Vosevi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10912814 | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Jun, 2037
(12 years from now) | |
| US11338007 | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Jun, 2037
(12 years from now) | |
|
US11338007 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of three antiviral compounds |
Dec, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: 18 July, 2021
Market Authorisation Date: 18 July, 2017
Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor
Dosage: TABLET
More Information on Dosage
VOSEVI family patents
79. Xerava patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10961190 | TETRAPHASE PHARMS | Crystalline forms of eravacycline |
Oct, 2037
(12 years from now) | |
| US11578044 | TETRAPHASE PHARMS | Crystalline forms of eravacycline |
Oct, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 27, 2028 |
Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient
NCE-1 date: 28 August, 2027
Market Authorisation Date: 27 August, 2018
Treatment: NA
Dosage: POWDER
More Information on Dosage
XERAVA family patents
80. Xofluza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10759814 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11306106 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-811) | Oct 16, 2022 |
| New Chemical Entity Exclusivity(NCE) | Oct 24, 2023 |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
NCE-1 date: 24 October, 2022
Market Authorisation Date: 24 October, 2018
Treatment: Method for post-exposure prophylaxis of influenza
Dosage: TABLET; FOR SUSPENSION
More Information on Dosage
XOFLUZA family patents
81. Xywav patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11426373 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Sep, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 21, 2023 |
| New Indication(I-870) | Aug 12, 2024 |
| Orphan Drug Exclusivity(ODE-231) | Jul 21, 2027 |
| Orphan Drug Exclusivity(ODE-361) | Jul 21, 2027 |
| Pediatric Exclusivity(PED) | Jan 21, 2028 |
| Orphan Drug Exclusivity(ODE-369) | Aug 12, 2028 |
Market Authorisation Date: 21 July, 2020
Treatment: Treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb administered ...
Dosage: SOLUTION
More Information on Dosage
XYWAV family patents
82. Yorvipath patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11918628 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(12 years from now) | |
| US11890326 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590207 | ASCENDIS PHARMA BONE | Dosage regimen for a controlled-release PTH compound |
Sep, 2037
(12 years from now) | |
| US11759504 | ASCENDIS PHARMA BONE | PTH compounds with low peak-to-trough ratios |
Sep, 2037
(12 years from now) | |
| US11857603 | ASCENDIS PHARMA BONE | PTH compounds with low peak-to-trough ratios |
Sep, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 09, 2027 |
| Orphan Drug Exclusivity(ODE-492) | Aug 09, 2031 |
Drugs and Companies using PALOPEGTERIPARATIDE ingredient
Market Authorisation Date: 09 August, 2024
Treatment: Treatment of hypoparathyroidism in adults
Dosage: SOLUTION
More Information on Dosage
YORVIPATH family patents
83. Zoryve patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11819496 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half-life |
Jun, 2037
(12 years from now) | |
| US11793796 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(12 years from now) | |
| US10940142 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(12 years from now) | |
| US12042487 | ARCUTIS | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
Jun, 2037
(12 years from now) | |
| US12005052 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half-life |
Jun, 2037
(12 years from now) | |
| US12011437 | ARCUTIS | Roflumilast formulations with an improved pharmacokinetic profile |
Jun, 2037
(12 years from now) | |
| US9907788 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(12 years from now) | |
| US11992480 | ARCUTIS | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
Jun, 2037
(12 years from now) | |
| US12005051 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half life |
Jun, 2037
(12 years from now) | |
| US9884050 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(12 years from now) | |
| US12016848 | ARCUTIS | Roflumilast formulations with an improved pharmacokinetic profile |
Jun, 2037
(12 years from now) | |
| US11129818 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half life |
Aug, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2026 |
| New Patient Population(NPP) | Oct 05, 2026 |
| New Strength(NS) | Jul 09, 2027 |
Drugs and Companies using ROFLUMILAST ingredient
Market Authorisation Date: 15 December, 2023
Treatment: Topical treatment of plaque psoriasis, including intertriginous areas, in patients 6 years of age and older; Topical treatment of mild to moderate atopic dermatitis; Topical treatment of seborrheic de...
Dosage: CREAM
More Information on Dosage
ZORYVE family patents
84. Ztalmy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603308 | MARINUS | Methods and compositions for treatment of epileptic disorders |
Aug, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 01, 2027 |
| Orphan Drug Exclusivity(ODE-395) | Jun 01, 2029 |
Drugs and Companies using GANAXOLONE ingredient
NCE-1 date: 01 June, 2026
Market Authorisation Date: 01 June, 2022
Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older
Dosage: SUSPENSION
More Information on Dosage
ZTALMY family patents
85. Zulresso patent expiration
Can you believe ZULRESSO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940156 | SAGE THERAP | Neuroactive steroids, compositions, and uses thereof |
Mar, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| New Patient Population(NPP) | Jun 16, 2025 |
Drugs and Companies using BREXANOLONE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: Method of treating postpartum depression
Dosage: SOLUTION
More Information on Dosage
ZULRESSO family patents
86. Zurzuvae patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11236121 | BIOGEN INC | Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid |
Aug, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11884696 | BIOGEN INC | Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid |
Dec, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2028 |
Drugs and Companies using ZURANOLONE ingredient
NCE-1 date: 01 November, 2027
Market Authorisation Date: 31 October, 2023
Treatment: Method of treating postpartum depression
Dosage: CAPSULE
More Information on Dosage
ZURZUVAE family patents
List of large molecules
1. List of Eylea large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10669594 | REGENERON PHARMACEUTICALS, INC. | Compositions and methods for detecting a biological contaminant |
Feb, 2037
(12 years from now) | |
| US11918785 | REGENERON PHARMACEUTICALS, INC. | Devices and methods for overfilling drug containers |
Jun, 2037
(12 years from now) | |
| US10182969 | REGENERON PHARMACEUTICALS, INC. | Aseptic piercing system and method |
Jul, 2037
(12 years from now) | |
| USD961377 | REGENERON PHARMACEUTICALS, INC. | Packaging |
Aug, 2037
(12 years from now) | |
| USD961376 | REGENERON PHARMACEUTICALS, INC. | Packaging |
Aug, 2037
(12 years from now) | |
| US11577025 | REGENERON PHARMACEUTICALS, INC. | Devices and methods for overfilling drug containers |
Oct, 2037
(12 years from now) | |
| US11680930 | REGENERON PHARMACEUTICALS, INC. | Methods and systems for chromatography data analysis |
Oct, 2037
(12 years from now) |
Ingredients: AFLIBERCEPT
2. List of Prolia And Xgeva large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US11275090 | AMGEN INC. | Quantitation of glycan moiety in recombinant glycoproteins |
Jul, 2037
(12 years from now) | |
| US11098079 | AMGEN INC. | Charged depth filtration of antigen-binding proteins |
Jul, 2037
(12 years from now) |
Ingredients: DENOSUMAB